The global biomaterial wound dressing market size is expected to reach USD 13.02 billion by 2033, registering a CAGR of 7.92% from 2025 to 2033, according to a new report by Grand View Research, Inc. Advances in biomaterial technology, which have led to the development of innovative and effective wound care products, rising prevalence of chronic diseases, improving healthcare infrastructure in emerging economies, are the key driving factors propel the biomaterial wound dressing market over the forecast period.
Moreover, the biomaterial wound dressing market has seen significant growth over the last few decades, owing to increasing product launches by key players, and rising R&D activities. For instance, in January 2023, Convatec introduced ConvaFoam, a range of advanced foam dressings that cater to the requirements of both healthcare providers and patients. ConvaFoam's versatility makes it an ideal dressing option for managing wounds and safeguarding the skin, as it can be used for various wound types, regardless of the wound's healing stage.
Similarly, in August 2023, Medela launched the Invia Integrated Dressing, which is designed to cater to all types of wounds, including closed surgical incisions. The sterile dressing can be utilized in both hospital and home settings for a period of up to seven days. As a result, product launches with additional benefits are expected to increase market growth for these biomaterial wound dressings over the projection period.
The rising prevalence of chronic disorders, such as diabetes and obesity has led to an increase in the number of patients with chronic wounds. Biomaterial wound dressings have been found to be effective in treating these wounds, which has driven demand for these products. For instance, according to WHO, in 2023, diabetes is a global health concern, with approximately 422 million people affected globally, mostly in low- and middle-income countries. Every year, 1.5 million deaths are directly linked to diabetes. The prevalence and number of cases of diabetes have been on a steady rise over the past few decades. These factors are expected to drive market growth over the forecast period.
Request a free sample copy or view report summary: Biomaterial Wound Dressing Market Report
By product, the natural segment led the market with the largest revenue share in 2024. The synthetic segment is expected to register the fastest CAGR during the forecast period.
By application, the chronic wounds segment led the market with the largest revenue share in 2024.
By end-use, the hospital segment led the market with the largest revenue share of 45.31% in 2024. The home healthcare segment is projected to witness the highest growth rate over the forecast period.
The biomaterial wound dressing market in North America held the largest share and accounted for 45.50% of global revenue in 2024. The biomaterial wound dressing market in the U.S. held the largest share in North America in 2024.
Grand View Research has segmented global biomaterial wound dressing market report on the basis of product, application, end-use and region:
Biomaterial Wound Dressing Product Outlook (Revenue, USD Million, 2021 - 2033)
Natural
Alginate
Honey
Collagen
Chitosan
Carboxymethyl Cellulose (CMC)
Others
Synthetic
Polyurethane
Silicone
Others
Biomaterial Wound Dressing Application Outlook (Revenue, USD Million, 2021 - 2033)
Chronic Wounds
Diabetic Foot Ulcers
Pressure Ulcers
Venous Leg Ulcers
Other Chronic Wounds
Acute Wounds
Surgical & Traumatic Wounds
Burns
Biomaterial Wound Dressing End-use Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals
Outpatient Facilities
Home Healthcare
Research & Manufacturing
Biomaterial Wound Dressing Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Mexico
Argentina
MEA
KSA
UAE
Kuwait
List of Key Players of Biomaterial Wound Dressing Market
ConvaTec Group PLC
Smith & Nephew PLC
Mölnlycke Health Care AB
B. Braun Melsungen AG
3M
URGO
Coloplast Corp.
Integra LifeSciences
Medline Industries, Inc.
Hollister Incorporated
MiMedx Group
Hartmann Group
Cardinal Health
Avita Medical
"The quality of research they have done for us has been excellent..."